Muscle mass as measured by MRI andDXA body composition increased significantly (~3 %) in thetreatment groups compared with placebo. It should be notedthat the results of a phase 1b trial of ACE-031 (clinicaltrials.gov NCT00952887) have been presented in abstract form andare summarized on the company website